Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Drug Class (2025 Share) (Antioxidants (28.45%), FXR Agonists), By Distribution Channel (2025 Share) (Hospital Pharmacies (47.32%), Online Pharmacies), By Route of Administration (2025 Share) (Oral Formulations (67.10%), Parenteral Products), By Age Group (Adults (64.72%), Geriatric Segment), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 17.47 Billion
CAGR (2026-2031)	15.71%
Fastest Growing Segment	Online pharmacies (fastest growth; 16.65% CAGR to 2031)
Largest Market	North America
Market Size (2031)	USD 41.93 Billion

Market Overview

The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market is expected to grow from USD 17.47 Billion in 2025 to USD 41.93 Billion by 2031 at a 15.71% CAGR. Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of hepatic conditions marked by excessive fat accumulation in liver cells, independent of significant alcohol intake, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Market growth is primarily driven by the escalating global epidemics of obesity and Type 2 diabetes, key risk factors that fuel disease prevalence. Additionally, the urgent need for effective pharmacological interventions for NASH, a condition currently without universally approved drug treatments, propels market demand.

According to the Global Liver Institute, in its 2025 Global State of Liver Health Report, approximately one in four people globally are affected by MASLD, the renamed form of fatty liver disease. Despite this vast patient pool, a significant challenge impeding market expansion involves the diagnostic complexity and invasive nature of liver biopsy, which remains the gold standard for accurately staging NASH, thus hindering broad patient screening and monitoring.

Key Market Drivers

Metabolic disorders driving NAFLD market growth
The rising global prevalence of metabolic disorders is a pivotal driver for the Non-Alcoholic Fatty Liver Disease market. Conditions like obesity and type 2 diabetes are highly correlated with NAFLD development and progression, including non-alcoholic steatohepatitis (NASH). As these metabolic epidemics escalate, the susceptible patient population grows, increasing demand for diagnostics and therapeutics. According to the World Obesity Federation, in its March 2025 'World Obesity Atlas 2025', the total number of adults living with obesity is projected to increase by over 115% between 2010 and 2030, from 524 million to 1.13 billion. This directly fuels the accelerating burden of liver steatosis and inflammation, fostering market expansion.

Non-invasive diagnostics and regulatory milestones expand market potential
Advancements in non-invasive diagnostic technologies are transforming the NAFLD market by alleviating invasive liver biopsy limitations. These innovations provide safer, more accessible, and repeatable methods for detecting and monitoring liver fat and fibrosis, enabling earlier diagnosis and effective disease management. Recognizing non-invasive tools as surrogate endpoints in clinical trials marks a significant development. For instance, according to the US Food and Drug Administration, in an August 27, 2025 statement, the agency accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic MASH with moderate-to-advanced liver fibrosis. This regulatory move facilitates faster drug development and broader patient identification. Commercial potential is also evident, with Madrigal Pharmaceuticals reporting net sales for REZDIFFRA reaching $431 million in the third quarter of 2026.

Download Free Sample Report

Key Market Challenges

Biopsy Invasiveness and Diagnostic Complexity Impede Screening and Monitoring
The primary challenging factor impeding the growth of the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market is the diagnostic complexity and the invasive nature of liver biopsy. This gold standard diagnostic tool for accurately staging non-alcoholic steatohepatitis (NASH), now metabolic dysfunction-associated steatohepatitis (MASH), presents a significant barrier to broad patient screening and effective disease monitoring.

Referral Gaps and Under-identification Limit Access to Diagnostics and Treatment
The reliance on an invasive procedure like liver biopsy limits widespread testing, leading to a substantial number of undiagnosed individuals or diagnoses occurring at advanced disease stages. This directly restricts the identifiable patient pool eligible for current and emerging pharmacological interventions. According to the Fatty Liver Foundation, in its 2025 "State of Steatotic (Fatty) Liver Care in America" survey, at least one in five individuals diagnosed with steatotic liver disease reported never receiving a referral to a specialist, underscoring significant gaps in the patient care pathway that impede access to advanced diagnostics and subsequent treatment. This under-identification of patients, coupled with delayed progression to specialist care, thus directly constrains the potential market for therapies by limiting the population engaged in active disease management.

Key Market Trends

Accelerated Regulatory Pathways Driving NAFLD Market Dynamics
Accelerated regulatory pathways for non-alcoholic fatty liver disease therapies are significantly influencing market dynamics by rapidly bringing novel treatments to patients. This expedited review process, often leveraging surrogate endpoints, allows for earlier market entry for promising drug candidates, addressing the critical unmet need in NAFLD. This trend stimulates further investment in drug development, as pharmaceutical companies perceive a clearer and faster path to commercialization. According to the U.S. Food and Drug Administration, in an August 15, 2025 statement, Wegovy (semaglutide) received accelerated approval for metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Shift Toward Targeted Therapies and Precision Medicine in NAFLD
Concurrently, the global NAFLD market is witnessing a pronounced shift towards developing targeted drug therapies, moving beyond broad-acting agents to precision medicine approaches. This trend involves identifying specific genetic, molecular, and metabolic pathways implicated in NAFLD progression, designing drugs to precisely modulate these targets for higher efficacy. This strategic focus enables therapies tailored to distinct patient subgroups, optimizing treatment outcomes and expanding the addressable population. According to Madrigal Pharmaceuticals, in a May 5, 2026 press release, the company paid an upfront fee of $25 million to Arrowhead Pharmaceuticals for the exclusive global license of ARO-PNPLA3, an siRNA asset targeting a specific genetic driver of MASH.

Segmental Insights

Online pharmacies driving rapid NAFLD market growth through accessibility and telemedicine.
The online pharmacies segment is experiencing the most rapid expansion within the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market. This robust growth stems from the increasing awareness surrounding NAFLD and its chronic management requirements, which necessitate long-term medication and lifestyle interventions. Online platforms offer unparalleled convenience and discreet access to necessary medications and supportive therapies for a sensitive condition that often demands sustained adherence. The widespread integration of telemedicine and digital prescription services further streamlines the process, enabling seamless virtual consultations and direct home delivery of treatments. This enhanced accessibility is particularly beneficial for NAFLD patients seeking consistent care, overcoming geographical barriers and improving overall treatment compliance.

Regional Insights

North America Emerges as Market Leader Fueled by Prevalence, Healthcare Infrastructure, and Regulatory Support
North America leads the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market due to its significant disease prevalence, driven by high rates of obesity and type 2 diabetes. The region benefits from advanced healthcare infrastructure and well-established networks of hepatology centers, which facilitate early diagnosis and comprehensive patient management. Furthermore, the strong regulatory support, notably from the U.S. Food and Drug Administration, has enabled accelerated approvals for novel therapies, such as Rezdiffra for non-alcoholic steatohepatitis. This is complemented by robust research and development investments and favorable reimbursement policies, collectively supporting the early adoption and market penetration of innovative treatments.

Recent Developments

• In August 2025, Novo Nordisk's Wegovy (semaglutide) received approval from the U.S. Food and Drug Administration for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis. This approval broadened the therapeutic landscape for MASH, as Wegovy was already established for obesity and type 2 diabetes. The drug's entry into the MASH market enabled Novo Nordisk to address patient populations through existing endocrinology, obesity, and diabetes care networks, in addition to hepatology specialists. This strategic expansion underscored the growing recognition of the interconnectedness between metabolic conditions and liver health, offering a new pharmacological option for patients.
• In October 2024, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Boehringer Ingelheim's survodutide (BI 456906) for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis. This designation was based on preliminary clinical data demonstrating potential improvements over existing therapies. Earlier in June 2024, the company had announced breakthrough Phase II trial sub-analysis results, showing that up to 64.5% of adults with F2 and F3 fibrosis achieved an improvement in fibrosis without worsening MASH after 48 weeks. This accelerated review will facilitate the development and potential availability of survodutide, a dual glucagon/GLP-1 receptor agonist, to address this serious liver disease.
• In June 2024, Viking Therapeutics announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, a liver-selective thyroid hormone receptor beta agonist, for patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The investigational drug demonstrated significant improvements in secondary histologic endpoints, including resolution of NASH without worsening of fibrosis in 63% to 75% of patients, compared to 29% in the placebo group. Additionally, a significant percentage of patients achieved at least a one-stage improvement in fibrosis without worsening NASH. These results support VK2809's potential as an effective treatment within the global NAFLD market, positioning it for further clinical development.
• In March 2024, Madrigal Pharmaceuticals received accelerated approval from the U.S. Food and Drug Administration (FDA) for Rezdiffra (resmetirom), in conjunction with diet and exercise, for treating adults with noncirrhotic nonalcoholic steatohepatitis (NASH), now often referred to as metabolic dysfunction-associated steatohepatitis (MASH), with moderate to advanced liver fibrosis. This marked a significant milestone as Rezdiffra became the first and only FDA-approved medication specifically for MASH. The approval was based on positive results from the Phase 3 MAESTRO-NASH trial, which demonstrated improvements in liver fibrosis and NASH resolution. Madrigal Pharmaceuticals commenced shipping the product in April 2024, initiating its commercial launch.

Key Market Players

• AbbVie, Inc.
• Madrigal Pharmaceuticals
• Intercept Pharmaceuticals
• Gilead Sciences, Inc.
• Novo Nordisk A/S
• Novartis
• Eli Lilly and Company
• Viking Therapeutics
• Akero Therapeutics
• 89bio

By Drug Class (2025 Share)	By Distribution Channel (2025 Share)	By Route of Administration (2025 Share)	By Age Group	By Region
Antioxidants (28.45%) FXR Agonists	Hospital Pharmacies (47.32%) Online Pharmacies	Oral Formulations (67.10%) Parenteral Products	Adults (64.72%) Geriatric Segment	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Drug Class (2025 Share):

• Antioxidants (28.45%)
• FXR Agonists

• Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Distribution Channel (2025 Share):

• Hospital Pharmacies (47.32%)
• Online Pharmacies

• Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Route of Administration (2025 Share):

• Oral Formulations (67.10%)
• Parenteral Products

• Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Age Group:

• Adults (64.72%)
• Geriatric Segment

• Non-Alcoholic Fatty Liver Disease (NAFLD) Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE